Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)

Market Cap	8.99B -12.2%
Revenue (ttm)	1.31B -21.8%
Net Income	57.66M -82.7%
EPS	0.14 -82.3%
Shares Out	411.25M
PE Ratio	153.18
Forward PE	48.58
Dividend	0.10 (0.47%)
Ex-Dividend Date	Jun 3, 2026

Volume	1,924,770
Open	21.48
Previous Close	21.48
Day's Range	21.36 - 21.88
52-Week Range	21.11 - 29.63
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:688739

Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company’s rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,781
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688739

Financial Performance

In 2025, SHA:688739's revenue was 1.39 billion, a decrease of -17.06% compared to the previous year's 1.68 billion. Earnings were 131.79 million, a decrease of -61.56%.